Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?
(2014) In Diabetes therapy : research, treatment and education of diabetes and related disorders- Abstract
- In a previously published study, vildagliptin showed a reduced risk of hypoglycemia versus glimepiride as add-on therapy to metformin at similar efficacy. Glimepiride was titrated from a starting dose of 2 mg/day to a maximum dose of 6 mg/day. It is usually assumed that the increased hypoglycemia with glimepiride was driven by the 6 mg/day dose; it was therefore of interest to assess whether the risk of hypoglycemia is also different between vildagliptin and a low (2 mg/day) dose of glimepiride.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4691349
- author
- Ahrén, Bo LU ; Foley, James Edward ; Dejager, Sylvie ; Akacha, Mouna ; Shao, Qing ; Heimann, Guenter ; Dworak, Markus and Schweizer, Anja
- organization
- publishing date
- 2014-09-18
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Diabetes therapy : research, treatment and education of diabetes and related disorders
- publisher
- Springer
- external identifiers
-
- pmid:25230877
- scopus:84919650730
- pmid:25230877
- wos:000209718400009
- ISSN
- 1869-6953
- DOI
- 10.1007/s13300-014-0082-y
- language
- English
- LU publication?
- yes
- id
- c8897711-3fa9-4a57-bae9-592d7ccdf5d0 (old id 4691349)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25230877?dopt=Abstract
- date added to LUP
- 2016-04-01 12:52:09
- date last changed
- 2024-01-09 04:12:32
@article{c8897711-3fa9-4a57-bae9-592d7ccdf5d0,
abstract = {{In a previously published study, vildagliptin showed a reduced risk of hypoglycemia versus glimepiride as add-on therapy to metformin at similar efficacy. Glimepiride was titrated from a starting dose of 2 mg/day to a maximum dose of 6 mg/day. It is usually assumed that the increased hypoglycemia with glimepiride was driven by the 6 mg/day dose; it was therefore of interest to assess whether the risk of hypoglycemia is also different between vildagliptin and a low (2 mg/day) dose of glimepiride.}},
author = {{Ahrén, Bo and Foley, James Edward and Dejager, Sylvie and Akacha, Mouna and Shao, Qing and Heimann, Guenter and Dworak, Markus and Schweizer, Anja}},
issn = {{1869-6953}},
language = {{eng}},
month = {{09}},
publisher = {{Springer}},
series = {{Diabetes therapy : research, treatment and education of diabetes and related disorders}},
title = {{Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?}},
url = {{https://lup.lub.lu.se/search/files/3020791/5322672}},
doi = {{10.1007/s13300-014-0082-y}},
year = {{2014}},
}